Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
- Status
- RECRUITING
- Phase
- PHASE2
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
(VELA) Study of BLU-222 in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of INCB123667 in Subjects With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
SMMART Adaptive Clinical Treatment (ACT) Trial
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
- Status
- RECRUITING
- Phase
- PHASE2
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Roll-over Study to Allow Continued Access to Ribociclib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4